Proteins & Peptides

Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations L452R and T478K. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally identified in India, and contains mutations L452R and E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R as well as deletion E156/F157. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R as well as deletion E156/F157. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R as well as deletion E156/F157. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified.  HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.

Recombinant human CLEC2D (C-type lectin domain family 2 member D), encompassing amino acids 60-191 (end). The N-terminal end of the protein is fused with the Fc fragment of a human IgG1 followed by an Avi-Tag™. The recombinant protein was affinity purified.

Recombinant human CLEC2D (C-type lectin domain family 2 member D), encompassing amino acids 60-191 (end). The N-terminal end of the protein is fused with the Fc fragment of a human IgG1 followed by an Avi-Tag™. The recombinant protein was affinity purified.

Recombinant human CD14 molecule, encompassing amino acids 20-336. This construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. HiP™ indicates a high purity protein (≥90% pure) and less than 10% aggregation as measured by gel filtration.